THE US Federal Trade Commission (FTC) is probing whether Abbott Laboratories and other companies that make baby formula colluded in bidding on state contracts, according to a document posted on the agency's website.
The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document, reported Reuters.
The document also stated that in 2022 the FTC began looking into potential collusion or coordination in bids to provide formula for the US Department of Agriculture's Women, Infants and Children (WIC) program that provides free formula to low-income families.
The document said studies showed that in addition to the money made from the contracts, the contract win tended to lead to better commercial sales.
"Although the boost in non-WIC sales motivates manufacturers to win WIC contracts, it may also create incentives to engage in collusive or coordinated market allocation, whereby incumbent WIC contract holders agree not to bid against each other," the document, written by Commissioner Alvaro Bedoya, said.
A spokesperson for Abbott commented, "Abbott is unaware of any factual basis to support the WIC-related investigation, and staff have not identified any reason to believe that Abbott or any of its competitors have coordinated or colluded regarding any WIC contract."
The above article was sent to subscribers in Pharmacy Daily's issue from 29 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 May 23
